Impact of Skin to Skin Contact on Maternal Satisfaction, Pain Scores, and Narcotic Usage After Cesarean Delivery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27103
- Novant Health Forsyth Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- non emergent cesarean deliveries term gestation age ASA I or II spinal anesthetic
Exclusion Criteria:
- contraindication to spinal anesthetic or to medications utilized emergence cesarean delivery under age 18 less than 37 weeks gestational age
Study Plan
How is the study designed?
Design Details
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: skin to skin
skin to skin initiated on all consented CS while in the operating room
|
initiating skin to skin is not currently the standard of care at our facility so there is 1 interventional arm for this study.
control group of no skin to skin until recovery room already established as is the standard of care.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maternal Evoked Pain Scores
Time Frame: up to 24 hours
|
maternal evoked pain is evaluated utilizing a 100 mm Sliding VAS scale with 0=no pain through 100=most severe pain ever
|
up to 24 hours
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Morphine Usage
Time Frame: up to 24 hours
|
24 hour morphine equivalents required in the operating room up to the initial 24 hours after delivery for pain management
|
up to 24 hours
|
|
Maternal Satisfaction With Anesthesia Care
Time Frame: up to 24 hours
|
maternal satisfaction with anesthesia care will be evaluated on post delivery day 1 utilizing a 100mm sliding scale where VAS 0= not satisfied at all up to 100= extremely satisfied
|
up to 24 hours
|
|
Maternal Satisfaction With Pain Control in the Operating Room
Time Frame: 24 hours
|
with pain control in the operating room will be evaluated on post delivery day 1 utilizing a 100mm sliding scale VAS 0= not satisfied at all up to 100= extremely satisfied
|
24 hours
|
|
Maternal Satisfaction With Postoperative Pain Control
Time Frame: 24 hours
|
with pain control at 24 hours postoperative will be evaluated on post delivery day 1 utilizing a 100mm sliding scale VAS 0= not satisfied at all up to 100= extremely satisfied
|
24 hours
|
|
Maternal Satisfaction-operating Room
Time Frame: 24 hours
|
maternal satisfaction with operating room atmosphere will be evaluated on post delivery day 1 utilizing a 100mm sliding scale VAS 0= not satisfied at all up to 100= extremely satisfied
|
24 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ashley Tonidandel, MD, Wake Forest University Health Sciences
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- IRB00033101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin to Skin Contact in Cesarean Deliveries
-
NCT06646393CompletedSkin to Skin Contact | Skin to Skin Contact in Cesarean Deliveries
-
NCT07422766RecruitingPregnancy | Cesarean Delivery | Skin to Skin Contact | Blood Pressure Measurement in Pregnancy
-
NCT07410754Not yet recruitingBreastfeeding | Skin to Skin Contact | Kangaroo Care | Cesarean Birth
-
NCT01894880CompletedEarly Skin-to-skin Contact
-
NCT06827522Not yet recruitingSkin to Skin Contact | Galvanic Skin Response
-
NCT06956859CompletedNewborn; Vitality | Skin to Skin Contact
-
NCT07223775CompletedCesarean Section | Kangaroo Care | Skin to Skin
Clinical Trials on skin to skin
-
NCT02687685Unknown
-
NCT05018910CompletedHeart Rate Variability | Preterm Infant
-
NCT04142099Unknown
-
NCT05975203RecruitingPreterm Birth | Infant Development | Mother-Infant Interaction
-
NCT05785806CompletedPostpartum Anxiety | Parturition; Precipitate
-
NCT07531758CompletedAnxiety | Breastfeeding | Ssc | Neonate | Maternal Blood Loss | Cesarean Birth
-
NCT07159477CompletedBonding | Attachment | Newborn Infant | Newborn Basic Care Training